Meta-Analyses Will Get Separate Guidance Documents From FDA And IoM
Executive Summary
The question of how to develop meta-analyses of clinical trials that can yield useful information on drug and biologic safety will be the subject of an FDA guidance and an important focus of two reports from the Institute of Medicine
You may also be interested in...
Clinical Safety Assessments Need Formal Protocols, FDA Says; Guidance On "Synthesis" Possible
To obtain information suitable for regulatory decision-making on a drug's safety, FDA expects the assessment of data across clinical trials to be based on a formal protocol that specifies the rules for collecting, analyzing and reporting the information.
Clinical Safety Assessments Need Formal Protocols, FDA Says; Guidance On "Synthesis" Possible
To obtain information suitable for regulatory decision-making on a drug's safety, FDA expects the assessment of data across clinical trials to be based on a formal protocol that specifies the rules for collecting, analyzing and reporting the information.
FDA Seeks Dedicated Meta-Analysis Team As Part Of PDUFA V User Fee Funding
FDA wants to create a meta-analysis team to conduct its own studies with funding from the next round of application user fees.